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ABSTRACT:
Translation initiation factors are over-expressed and/or activated in many 
human cancers and may contribute to their genesis and/or progression.  Removal 
of physiologic restraints on translation initiation causes malignant transformation. 
Conversely, restoration of physiological restrains on translation initiation reverts 
malignant phenotypes. Here, we extensively characterize the anti-cancer activity 
of two small molecule inhibitors of translation initiation: #1181, which targets the 
eIF2∙GTP∙Met-tRNAi ternary complex, and 4EGI-1, which targets the eIF4F complex. In 
vitro, both molecules inhibit translation initiation, abrogate preferentially translation 
of mRNAs coding for oncogenic proteins, and inhibit proliferation of human cancer 
cells. In vivo, both #1181 and 4EGI-1 strongly inhibit growth of human breast and 
melanoma cancer xenografts without any apparent macroscopic- or microscopic-
toxicity. Mechanistically, #1181 phosphorylates eIF2α while 4EGI-1 disrupts eIF4G/
eIF4E interaction in the tumors excised from mice treated with these agents. These 
data indicate that inhibition of translation initiation is a new paradigm in cancer 
therapy.
INTRODUCTION
Eukaryotic translation is regulated by the eukaryotic 
translation initiation factors (eIFs), features of mRNAs, 
and signaling pathways. Two multi-protein complexes are 
rate limiting for translation initiation. The eIF4F complex 
is formed by the scaffolding protein eIF4G the RNA 
helicase eIF4A, and the mRNA cap binding protein eIF4E. 
The ternary complex (TC) is formed by the interaction 
of eIF2 with GTP and initiator methionine tRNA (Met-
tRNAi). The eIF4F complex binds to the mRNA 5’ cap 
structure and associates with 40S ribosomal subunit, 
the TC, and other translation initiation factors to form 
the 48S pre-initiation complex that scans the mRNA 5’ 
untranslated region (5’UTR) to locate the AUG initiation 
codon. 
Translation initiation plays a critical role in cell 
growth and malignant transformation [1-6]. In quiescent 
cells eIF4E-binding proteins (4E-BPs) restrict the 
abundance of the eIF4F complex, while phosphorylation 
of eIF2α on S51 restricts the availability of the TC. In 
proliferating cells, phosphorylation of 4E-BPs reduces 
their affinity for eIF4E and increases the abundance of 
the eIF4F complex [7]. Similarly dephosphorylation of 
eIF2α allows for eIF2B catalyzed GDP-GTP exchange 
on the eIF2∙GDP, and increases the abundance of the TC. 
Malignant transformation is associated with a preferential 
increase in the translation of mRNAs encoding for 
growth factors and/or oncogenic proteins. These mRNAs 
contain long and highly structured 5’UTRs, multiple 
upstream untranslated open reading frames (uORFs), or Oncotarget 2012; 3: 869-881 870 www.impactjournals.com/oncotarget
other features that reduce their translational efficiency 
and  render  them  highly  dependent  on  the  activity  of 
translation initiation factors [4, 5]. Housekeeping proteins, 
on the other hand, are coded for by efficiently translated 
mRNAs with short and simple 5’UTRs. Unrestricted 
translation, therefore, preferentially increases the 
expression of oncogenic proteins and promotes malignant 
transformation [8-11]. Consistently, restricting translation 
initiation by reducing the abundance of either eIF4F or 
TC preferentially decreases the expression of oncogenic 
proteins thereby reverting malignant phenotypes [12-14].
Levels of eIF4E [8, 15-19], eIF4G [6, 20] and eIF4A 
[21, 22] are frequently up-regulated in human cancers. 
Notably,  in  head  and  neck  and  breast  cancers,  levels 
of eIF4E correlate with disease progression and poor 
prognosis [8, 10, 18, 23]. Similarly, in non-Hodgkin’s 
lymphomas  and  thyroid  carcinomas,  levels  of  eIF2α 
correlate with disease status [24-26]. 
In experimental models of cancer forced expression 
of  eIF4E  [27],  of  a  constitutively  active  but  non-
phosphorylatable  mutant  of  eIF2α  (eIF2α-S51A)  [11] 
or of initiator Met-tRNAi [28] transforms immortalized 
fibroblasts. Conversely, decreasing the levels of eIF4E 
by treatment with eIF4E anti-sense RNA or its activity 
by ectopic expression of 4E-BPs partially reverses the 
transformed phenotypes [9, 12, 13]. Pharmacologically, 
treatment with eIF4E anti-sense RNA or agents that induce 
phosphorylation of eIF2α inhibits translation initiation and 
proliferation of cancer cells in vitro, and reduces tumor 
growth  in  animal  models  of  human  cancers  [29-31]. 
Similarly, inhibitors of the mammalian target of rapamycin 
(mTOR), which reduces phosphorylation of 4E-BPs [32, 
33], exert anti-cancer activity in vitro [14, 34] and in vivo 
[35]. Finally, small molecules such as pateamine A and 
Figure 1: #1181 and 4EGI-1 inhibit translation initiation. A) CRL-2813 human melanoma cells were treated with the indicated 
concentrations of #1181, cell lysates were probed with antibodies specific to S51 phosphorylated eIF2α, total eIF2α, CHOP and β-Actin. 
B) CRL-2813 cells were treated with the indicated concentrations of 4EGI-1, eIF4E was pulled-down from the lysates using M7GDP 
Sepharose cap affinity column. Proteins were eluted from the column with free M7GDP and probed with antibodies specific to eIF4G, eIF4E 
or 4E-BP1. C) Cells were treated with 10 µM #1181 or 50 µM 4EGI-1 for 3 hours, cytoplasmic extracts were overlaid on 15-60% sucrose 
gradient and subjected to ultracentrifugation. The gradients were eluted from the bottom under constant monitoring at 254 nm.Oncotarget 2012; 3: 869-881 871 www.impactjournals.com/oncotarget
silvestrol - reduce the activity of the eIF4F complex by 
modulating  the  activity  of  eIF4A  thereby  suppressing 
translation initiation [36-38]. Taken together, these data 
indicate that translation initiation is a promising new 
paradigm and an attractive target for the development of 
anti-cancer agents.
We  previously  reported  the  identification  of  the 
translation initiation inhibitor 4EGI-1, which binds to 
eIF4E and thereby disrupts eIF4E/eIF4G interaction [39]. 
Additionally, we reported on  the development of #1181 
[40], which causes eIF2α phosphorylation [40] thereby 
inhibiting cap-dependent translation and proliferation of 
cancer cells. These findings suggested that 4EGI-1 and 
#1181 are suitable probes for testing the hypothesis that 
small molecule inhibitors of translation initiation are 
mechanism specific anti-cancer agents. 
Here we report the anti-cancer efficacy, mode of 
action, pharmacokinetics, and toxicity profiles of 4EGI-
1 and #1181. Both agents inhibit translation initiation 
and preferentially abrogate expression of oncogenic 
proteins in vitro. In vivo, 4EGI-1 and #1181 strongly 
inhibit tumor growth in xenograft models of human breast 
and melanoma cancers with no sign of macroscopic- or 
microscopic-toxicity at therapeutic doses. In xenograft 
tumors, #1181 phosphorylates eIF2α and 4EGI-1 disrupts 
eIF4G/eIF4E interaction. Both agents inhibit expression of 
oncogenic proteins such as cyclin E, cyclin D1, c-Myc and 
Bcl-2 in vivo. We conclude that translation initiation can 
be pharmacologically targeted for cancer therapy.
Figure 2: #1181 increases the recruitment of ATF-4, a downstream effector eIF2α phosphorylation, to heavy polysomes 
but does not inhibit protein synthesis in cell-free extracts. A) Total RNA was prepared from CRL-2813 cells incubated for 3 
hours in the presence or absence of #1181. ATF-4 mRNA levels were determined by QRT-PCR. B) The distribution of ATF-4 mRNA along 
the polysome profile was determined using fractioned RNA from polysome profiles shown in Figure 1C. C) The wild type eIF2α or S51A 
mutant eIF2α expressing PC3 cells were treated with #1181 in indicated concentrations [48]. The growth inhibition was measured by SRB 
assay. D)  The in vitro translation assay was performed according to the protocol of Retic Lysate IVTTM Kit (Ambion, cat. #AM1200). 
The effect of #1181 on the translation efficiency of luciferase RNA (Promega, cat. #L4561) was determined by measuring the luminescence 
with Wallac Envision Reader.Oncotarget 2012; 3: 869-881 872 www.impactjournals.com/oncotarget
RESULTS
In vitro characterization of #1181 and 4EGI-1.
Based  on  the  high  prevalence  of  breast  cancer 
and melanoma, we screened approximately 20 different 
melanoma and breast cancer cell lines using a combination 
of IC50 in vitro (Supplemental Table S1) and tumorigenicity 
in nude mice as final selection criteria. Consequently, 
human melanoma (CRL-2813) and breast cancer (MCF-7 
and CRL-1500) cells were chosen for testing the in vitro 
and in vivo efficacy of #1181 and 4EGI-1. 
Inhibition of translation initiation in vitro:  In 
mechanistic assays, #1181 induced phosphorylation of 
eIF2α  (Figure 1A). As shown previously, 4EGI-1 reduced 
the association of eIF4G with eIF4E (Figure 1B) [39]. 
Both compounds shifted the polysome profile of cancer 
cells from heavy to light polysomes or free ribosomal 
subunits (Figure 1C), clearly demonstrating that #1181 
and 4EGI-1 inhibit translation initiation. Furthermore, 
#1181 induced expression of C/EBP homology protein 
(CHOP) and activating transcription factor 4 (ATF-4)- two 
downstream effectors of eIF2α phosphorylation (Figures 
1A, 2A, and 2B). In mechanistic assays, #1181 inhibited 
cancer  cell  proliferation  in  an  eIF2α  phosphorylation 
dependent manner. This was evidenced by the fact that 
replacing  endogenous  eIF2α  with  recombinant  eIF2α 
S51A mutant rendered the cancer cells resistant to 
inhibition of cell proliferation by #1181 as compared 
to cells in which endogenous eIF2α was replaced with 
recombinant  wild  type  eIF2α  (Figure  2C).  Consistent 
with demonstration that in intact cells, #1181 induces 
phosphorylation of eIF2α via Ca++ release from internal 
stores [40], this compound had no direct inhibitory effect 
on protein synthesis in cell-free lysates (Figure 2D). 
Expression  of  most  proteins  involved  in 
cell proliferation and malignant transformation is 
translationally controlled and is highly dependent on the 
activity of translation initiation factors. To determine if 
#1181 and 4EGI-1 translationally downregulate expression 
of oncogenic proteins, we performed Western blot (WB) 
and quantitative real time PCR (QRT-PCR) analyses of 
Figure 3: #1181 and 4EGI-1 preferentially inhibit expression of oncogenic proteins. A) CRL-2813 human melanoma cells 
were treated with the indicated concentrations of #1181 or 4EGI-1, lysates were prepared and probed with antibodies specific to Bcl-2, 
b-FGF, c-Myc, Cyclin D1, Cyclin E, Survivin, α-Tubulin β-Actin, and Ubiquitin. B) RNA was prepared from similarly treated cells and 
levels of cyclin D1, cyclin E, survivin, b-FGF, c- Myc, Bcl-2 and β-actin mRNAs were determined. Shown are mRNA levels for c-myc 
and bcl-2 relative to controls. Data for other mRNAs are shown in the Supplementary Figure S4. C) The level of various oncogenic and 
housekeeping mRNAs in the polysome fractions of cells treated with vehicle, #1181 and 4EGI-1 were determined by QRT-PCR.Oncotarget 2012; 3: 869-881 873 www.impactjournals.com/oncotarget
lysates from CRL-2813 human melanoma cells treated 
with #1181, 4EGI-1 or vehicle (DMSO). Figure 3A shows 
that both compounds significantly reduced the expression 
of c-Myc, Cyclin D1, Cyclin E, Bcl-2, bFGF and Survivin 
while the expression of housekeeping proteins such as 
β-Actin, α-Tubulin and Ubiquitin was not affected (for 
quantitation of WB data see Supplemental Figure S1). 
Down-regulation of most oncogenic proteins was likely 
translational because the compounds had minimal effects 
on the levels of the respective mRNAs (Figure 3B and 
Supplemental Figure S2). In a few instances, and only at 
high concentrations of #1181 or 4EGI-1, accumulation of 
oncogenic mRNAs was reduced (Supplemental Figure 
S2). These  findings  are  consistent  with  the  view  that 
inhibitors of translation initiation preferentially affect 
the expression of oncogenic proteins. This was further 
confirmed by QRT-PCR measuring the distribution of 
mRNAs in the polysome fractions by RT-PCR (Figure 
3C). The shift in polysome profile caused by treatment 
with #1181 or 4EGI-1 (Figure 1C) was associated with a 
preferential shift in the distribution of oncogenic mRNAs 
from heavy to light polysomes or polysome-free fractions. 
Both #1181 and 4EGI-1 translationally reduced the 
expression of mTOR protein (Figure 4A and Supplemental 
S3) and the phosphorylation of 4E-BP1 (Figures 4A) with 
no effect on the levels of mTOR mRNA (Figure 4B). 
This is consistent with the known pleiotropic effects of 
the mTOR [41]. It must be noted; however, that 4EGI-1 
inhibits eIF4E/eIF4G interaction independently of 4E-BP1 
binding to eIF4E [39]. Furthermore, neither  #1181 nor 
4EGI-1 impinge directly on the PI3-K Akt pathway that is 
activated in the MCF-7 and CRL-1500 breast cancer cells, 
or the B-raf/Erk pathway that is activated in CRL-2813 
melanoma cell line, as demonstrated by the experiment 
depicted in Supplemental Figures S4A and S4B. 
In vivo characterization of #1181 and 4EGI-1: To 
assess the in vivo anti-cancer activity of #1181 and 4EGI-
1 we attempted to determine the maximum tolerated dose 
(MTD) of both agents by injecting groups of 5 male and 
5 female nude mice with different intraperitoneal (i.p.) 
Figure 4: Translation initiation inhibitors abrogate mTOR expression and 4E-BP1 phosphorylation. A) CRL-2813 cells 
were treated with the indicated concentrations of #1181 or 4EGI-1. Cell lysates were probed with antibodies specific to mTOR, 4E-BP1 
phosphorylated (p4E-BP1) on the indicated residues, total 4E-BP1, and β-actin. B) Cells were treated as in A and level of mTOR mRNA in 
treated cells relative to control cells was determined by QRT-PCR.Oncotarget 2012; 3: 869-881 874 www.impactjournals.com/oncotarget
doses of each compound for 5 consecutive days. This 
was followed by observation for an additional 14 days. 
At the concentrations used, neither compound caused 
significant weight loss, behavioral changes, reduced daily 
food intake, or any other overt toxicity (Figure 5). Limited 
solubility of compounds in aqueous buffers precluded 
further dose escalation to determine MTD. The long-term 
organ toxicity was evaluated by treating mice i.p. for 21 
days with daily injections of the highest compound dose 
used in the efficacy studies described below. Necropsy 
pathological analysis of these mice did not reveal any 
macro- or microscopic evidence of organ toxicity (Figure 
6 and Supplemental S5).
Plasma  concentration-time  profiles  of  the  two 
compounds in mice treated i.p. with a 25 mg/kg of #1181 
in 200 µL of corn oil or 50 mg/kg of 4EGI-1 in 25 µl of 
DMSO are presented in Supplemental Figure S6A. Both 
compounds were rapidly absorbed from the peritoneal 
cavity, with peak concentrations C(max) =  5.2 µM and 
139 µM occurring at t(max) = 52 min and 43 min for 
#1181 and 4EGI-1, respectively. Plasma concentrations of 
both compounds decayed in a mono-exponential manner 
with half-life t1/2 = 1.6 h for #1181 and 3.4 h for 4EGI-
1.  Values of the apparent total body clearance were 
CL/F = 90.4 and 2.4 ml/min/kg for #1181 and 4EGI-1, 
respectively.  Furthermore, as shown in Supplemental 
Figures S6B and S6C, the plasma concentration of #1181 
or 4EGI-1 exhibited excellent dose dependence. The 
doses and treatment regimens were chosen based on these 
findings. Due to its lower plasma exposure and shorter 
half-life, #1181 was administered twice daily, (b.i.d.) 
while 4EGI-1 was administered once a day (q.d.).
Inhibition of tumor growth:
Mice bearing CRL-2813 human melanoma tumors 
(apparent volume of ≈ 200 mm3) were randomized into 
control and treatment groups. Compound #1181 was 
dissolved in corn oil and injected i.p. 175 mg/kg b.i.d 
in 125 µl corn oil 12 h apart. Control animals received, 
by the same regimen, the same daily amount of corn oil.   
Figure 7A (left panel) and Supplemental Figure S7A (left 
panel) show that #1181 totally abolished human melanoma 
xenograft tumor growth. 
To determine if #1181 inhibits growth of mammary 
tumors, estrogen-dependent MCF-7 human breast cancer 
cells were inoculated into the fat pad of the 4th inguinal 
mammary gland of female mice implanted with slow 
release 17-β-estradiol pellets in the subscapular region. 
Animals bearing ≈150 mm3 tumors were randomized into 
Figure 5: Maximum tolerated dose (MTD) assay for #1181 and 4EGI-1. MTD was assessed by injecting groups of 5 male 
and 5 female nude mice with different intra-peritoneal (i.p.) doses of each compound for 5 consecutive days followed by observation for 
additional 15 days, in accord with NIH protocols. At the concentrations used, injection of either compound did not result in significant 
weight loss, reduced daily food intake, behavioral changes or any other observable sign of toxicity.Oncotarget 2012; 3: 869-881 875 www.impactjournals.com/oncotarget
control and treatment groups and administered #1181 i.p. 
at 60 or 140 mg/kg b.i.d. in 100 µl of corn oil 12 h apart or 
the same regimen of daily amount of corn oil.  Figure 7A 
(right panel) and Supplemental Figure S7A (right panel) 
show that #1181 caused a dose-dependent inhibition of 
MCF-7 human breast cancer tumor growth; the highest 
dose induced a ≈ 30% regression of the tumors.
To determine the anti-tumor efficacy of 4EGI-1, 
mice bearing ≈ 200 mm3 human melanoma tumors were 
randomized into three groups and injected i.p. with 25 
or 75 mg/kg q.d. 4EGI-1 in 12.5 µl DMSO or 12.5 µl 
DMSO.  Figure 7B (left panel) and Supplemental Figure 
S7B (left panel) show that 4EGI-1 significantly, and dose-
dependently, inhibited human melanoma xenograft tumor 
growth.  Similarly, mice bearing orthotropic ≈200 mm3 
CRL-1500 derived xenograft breast tumors were treated 
i.p.  with  75mg/kg  q.d.  of  4EGI-1  in  12.5  µl  DMSO, 
with control animals receiving the same daily amount 
of DMSO. Figure 7B (right panel) and S7B (right panel) 
show that 4EGI-1 caused a significant inhibition of CRL-
1500 human breast tumor growth.
Molecular analysis of tumors 
To assess their in vivo mode of action, we evaluated 
the effects of #1181 and 4EGI-1 on the phosphorylation 
of eIF2α and disruption of eIF4E/eIF4G interaction in the 
excised tumors. Paraffin embedded sections of melanoma 
and breast tumors excised from mice treated with #1181 
or vehicle were stained with antibodies specific to S51 
phosphorylated or total eIF2α. Figures 8A and 8B show 
that #1181 significantly increased the phosphorylation 
of eIF2α in the tumors. The in vivo effects of compound 
4EGI-1 on the formation of eIF4F complex were 
investigated by pulling-down eIF4E from tumor lysates 
by 7-methylguanosine diphosphate (M7GDP)-Sepharose 
affinity  chromatography  followed  by  WB  analysis  of 
eIF4E, eIF4G and 4E-BP1. Tumors from mice treated 
with 4EGI-1 showed a reduced association of eIF4E with 
eIF4G and an increased association of eIF4E with 4E-BP1 
(Figures 8C and 8D). 
We also stained tumor sections with antibodies 
specific to phosphorylated 4E-BP1 and oncogenic and 
growth promoting proteins such as cyclin D1, cyclin E, 
c-Myc, Bcl-2, and VEGF. Consistent with their in vitro 
activities both #1181 and 4EGI-1 reduced phosphorylation 
of 4E-BP1 (Figure 9) and the expression of oncogenic 
proteins in the tumors (Figure 10 and Supplemental 
Figures S8-S10).  Both agents significantly reduced the 
expression of proliferating cell nuclear antigen (PCNA, 
Supplemental Figures S8-S10) without any effect on the 
expression of B-raf, phosphorylated Erk1/2 or Akt, or 
increase in the proportion of apoptotic cells as determined 
by TUNEL assay (Supplemental Figure S11).  
DISCUSSION
Excessive  activation  and/or  overexpression 
of translation initiation factors cause malignant 
transformation and maintenance of transformed 
phenotypes in vitro and in vivo [8-11, 27]. Translation 
Figure 6: #1181 displays no organ toxicity. Nude mice (5 mice each group) were treated i.p. with 175 mg/kg b.i.d. #1181 or vehicle 
b.i.d. for 21 days. At the end of treatment, mice were euthanized, major organs were harvested, stored in Bouin’s solution, and sectioned for 
microscopic examination. The displayed slides are representative of the sample pool available.Oncotarget 2012; 3: 869-881 876 www.impactjournals.com/oncotarget
initiation factors are also implicated in the genesis, 
maintenance and progression of human cancers [8, 16-19] 
suggesting that translation initiation may be an attractive 
target for cancer therapy. However, the lack of potent and 
specific small molecule inhibitors of translation initiation 
has hampered the experimental assessment of whether the 
translation initiation machinery can be pharmacologically 
targeted for therapeutic purposes. 
The work reported here provides direct evidence 
that inhibition of translation initiation with either #1181 
or 4EGI-1 abrogates tumor growth in two animal models 
of  human  cancer.  Compound  #1181  induces  eIF2α 
phosphorylation, which reduces the abundance of the 
TC. Compound 4EGI-1 inhibits eIF4E/eIF4G protein-
protein interaction, which reduces the abundance of 
the eIF4F complex [39, 40]. Both compounds abrogate 
tumor growth and cause comparable down-regulation of 
oncogenic proteins in vivo. Importantly, histo-pathological 
and hematological analysis of treated tumor-bearing 
mice demonstrated that neither 4EGI-1 nor #1181 cause 
any sign of overt toxicity. Our demonstration that both 
compounds recapitulate in vivo their biological activities 
in vitro validates the concept that the anti-cancer effect of 
both compounds is most likely mediated by inhibition of 
translation initiation. 
One of the oncogenic proteins translationally 
down regulated by both 4EGI-1 and #1181 is mTOR, 
which couples PI3K/Akt signaling with assembly of 
the eIF4F complex by inducing phosphorylation of 4E-
BP1. This in-turn reduces 4E-BP1’s affinity for eIF4E 
and makes it available for eIF4F assembly. This suggests 
the 4EGI-1 and #1181 may create a feedback loop that 
further potentiates their inhibitory effect, and potentially 
highlights another major advantage of small molecule 
inhibitors of translation initiation for cancer therapy. 
Our  findings  indicate  that  by  depriving  cancer 
Figure 7: In vivo efficacy of translation initiation inhibitors for cancer therapy. Mouse carrying xenografted human melanoma 
or breast cancer (~150 mm3) were randomly distributed to control and treatment groups and treated i.p. with the indicated daily doses of 
#1181 b.i.d. (A) or 4EGI-1 q.d. (B). Tumor dimensions were measured weekly and tumor volumes were calculated.Oncotarget 2012; 3: 869-881 877 www.impactjournals.com/oncotarget
cells of the oncogenic proteins critical for maintaining 
their transformed phenotype, small molecules #1181 
and 4EGI-1 target cancer cells at their “Achilles 
heel” [42, 43]. Targeting the expression of multiple 
oncogenic proteins that the cancer cells are addicted to 
represents a new paradigm in cancer therapy and has 
distinct  advantages  over  both  conventional  genotoxic 
therapies and recently developed therapeutic agents that 
target a single oncogene/survival factor [44]. The latter 
therapeutic approach is compromised because cancer 
cells develop resistance to the drug by either activating 
redundant/alternate pathway(s) to compensate for the loss 
of the targeted molecule or sustain mutations that renders 
the primary target refractory to the therapeutic agent 
[45]. Significant progress in resolving the structure of 
translation initiation factors [46, 47] as well as discovery 
of novel inhibitory agents [48], should significantly aid 
discovery  and  development  of  translation  initiation 
inhibitors. In conclusion, inhibition of translation initiation 
is a promising complement to the prevailing anti-cancer 
therapies because it is aimed at the convergent point of 
oncogenic  and  proliferative  pathways.  This  paradigm 
represents a solid rational for developing and testing small 
molecule inhibitors of translation initiation in clinical 
studies for anti-cancer therapy.
MATERIALS AND METHODS
Cell growth assay.
 All cell lines were purchased from American 
Type Culture Collection (ATCC), maintained per ATCC 
Figure 8: #1181 causes phosphorylation of eIF2α while 4EGI-1 disrupts eIF4E/eIF4G interactions in vivo. A) and B) 
human CRL-2813 melanoma (A) and MCF-7 breast (B) xenograft carrying mice were treated i.p. with #1181 (175 mg/kg and 120 mg/kg, 
b.i.d., respectively) for three days, tumors were excised, formaldehyde fixed, and stained with antibodies specific to S51 phosphorylated 
and total eIF2α. Bar graphs show ratio of phosphorylated to total eIF2α. The displayed section are representative of numerous sequential 
slices obtained. C and D) human CRL-2813 melanoma (C) and CRL-1500 breast (D) xenograft carrying mice were treated i.p. with 
indicated doses of 4EGI-1 for three days, tumors were excised, lysed, and eIF4E was pulled-down using M7GDP affinity column. Eluted 
proteins were blotted with antibodies specific to eIF4G, eIF4E or 4E-BP1.Oncotarget 2012; 3: 869-881 878 www.impactjournals.com/oncotarget
protocols and utilized within 6 months of thawing each 
vial. The inhibition of cell growth was measured by the 
sulforhodamine B (SRB) assay [31]. 
Polysome profiles.
Polysome profiles were obtained by the sucrose 
density gradient centrifugation method [29]. 
Animal studies.
CRL-2813 (451Lu, B-raf V600E mutant) melanoma 
cells were injected subcutaneously (2.5 x 105 cells in 0.1 
ml of 50% matrigel) into 6-week-old male nude mice 
(Charles River Laboratories). Tumor-bearing mice were 
randomized into control and treatment groups, treated 
intra-peritoneal (IP) with the vehicle, 4EGI-1 (75 and 25 
mg/kg q.d. in 12.5 µl DMSO) or #1181 (175 mg/kg b.i.d.   
in 125 µl corn oil), Tumor volumes were calculated as in 
[30] and results analyzed by Student’s t-test. 
Female mice implanted with 90 day slow release 
17-β-eastradiol  pellet  in  the  subscapular  region  were 
inoculated  with  MCF-7  (HTB-22,  PI3Kα  mutant)  or 
CRL-1500 (ZR75-1, PTEN deficient) human breast cancer 
cells into the 4th inguinal gland. Tumors were allowed to 
grow 150 mm3 size, animals were randomly distributed to 
control and treatment groups. Mice bearing MCF-7 tumors 
were treated IP with 140 or 60 mg/kg b.i.d.  #1181 in 100 
µl corn oil or corn oil alone. Mice bearing CRL-1500 
xenografts were treated i.p. with 75 mg/kg q.d. 4EGI-1 
in 1.5 µl DMSO or DMSO alone. All animal studies were 
approved by the Harvard Medical School Institutional 
Animal Care and Use Committee and conducted in 
accordance with the Animal Care and Use Committee 
approved protocols.
Immunohistochemistry. 
Formalin-fixed, paraffin-embedded tumor sections 
were immunostained with antibodies and counter-stained 
with hematoxylin. List and sources of antibodies are given 
in Supplemental Table S1. Pictures were taken with Nikon 
(ECLIPSE) microscope via Nikon (Plan Fluor) lenses by 
Nikon (TE2000-E) camera. Images were acquired in JPEG 
format using SPOT Advanced software and staining was 
Figure 9: #1181 and 4EGI-1 down-regulate the phosphorylation of 4E-BP1 in tumors. The sections from the excised 
tumors taken from the efficacy studies were stained with phospho-4E-BP1 (Thr37/46) antibody (Cell Signaling, cat. #2855). The data was 
quantified by ProImage software. The displayed section are representative of numerous sequential slices obtained.Oncotarget 2012; 3: 869-881 879 www.impactjournals.com/oncotarget
quantified with ProImage software.  All antibodies used 
for these studies are listed in Supplemental Table S2.
Western blot analysis.
The WB analysis was performed as described [49]. 
For eIF2α phosphorylation, cells were treated with either 
#1181 or DMSO for 1 hour. For analysis of other proteins, 
cells were incubated for 8 hours in the presence or absence 
of each compound. 
Quantitative Real-time PCR analysis.
Cells were incubated for 8 hours in the presence 
or absence of the compounds. The FastLane Cell SYBR 
Green Kit (Qiagen) was used to purify and analyze the 
mRNA levels with an Applied Biosystems Thermocycler. 
RT-PCR quantitation of the mRNAs relative to β-actin 
mRNA was done using the ΔΔCT method. Sequence-
validated QuantiTec probes for bcl-2, bFGF, survivin, 
mTOR, cyclin D1, cyclin E, c-Myc, and β-actin purchased 
from Qiagen Bio-technology were used for these mRNAs. 
QRT-PCRs  were  also  performed  to  determine  the 
polysome profile shifts for β-actin, mTOR, Bcl-2, c-Myc, 
cyclin  D1  and ATF-4  using  total  RNA  isolated  from 
polysome fractions.
m7GTP Pull-Down assay.
CRL-2813 cells were treated with 4EGI-1 or DMSO 
for 8 hours, harvested by centrifugation and lysed. The 
interaction of eIF4E with eIF4G was determined by the 
m7GTP Pull-Down assay as described [39]. For in vivo 
pull-down experiments, extracts of tumors excised from 
mice treated with either 4EGI-1 or DMSO were similarly 
analyzed.
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